Dediabetes Logo
Evidence Hub
Learn what works
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign up
Research Summary
Analyzed using Evidence Intelligence™

Tirzepatide improves HbA1c via weight loss in type 2 diabetes.

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated July 4, 2026

Key finding

The difference in mean HbA1c change from baseline at 40 weeks between tirzepatide and the placebo group ranged from -20.0 to -14.6 mmol/mol.

The study investigated the effects of tirzepatide on HbA1c levels, highlighting the role of weight loss in these reductions.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Extended (5–20+ y)

Risk of bias

Some Concerns

Save this study and add notes to your research library.

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

The study investigated the effects of tirzepatide on HbA1c levels, highlighting the role of weight loss in these reductions.

Clinical relevance

This study is significant as it highlights the dual mechanism of tirzepatide in managing diabetes, emphasizing the importance of weight loss in achieving better glycemic control. Understanding these effects can help healthcare providers tailor treatment plans for patients with type 2 diabetes.

Keep in mind

Effectiveness data was unclear for some outcomes. The study's population may not be representative of all diabetes patients. Long-term effects beyond 40 weeks were not assessed.

Published in

Journal Reference

Publication details and source links for this paper.

Tina V, Maciej TM, Palash S, Vivian TT, Krishna KC, Jacek K. Tirzepatide-induced HbA1c reductions are mediated through weight loss effects. Diabetes, Obesity & Metabolism. 2025;27(10):5498-5505. doi:10.1111/dom.16592

View DOIView on PubMedView on PMC

Main Effects

Tirzepatide reduced HbA1c levels by -20.0 to -14.6 mmol/mol compared to placebo.

Weight loss accounted for 12%-27% of the HbA1c reduction when tirzepatide was used alone.

25%-45% of the HbA1c difference between tirzepatide and semaglutide was independent of weight loss.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Tirzepatide and HbA1c, Weight loss dependent effect on HbA1c, Weight loss independent effect on HbA1c.

This study contributes evidence to

Intervention

Tirzepatide

Outcome

HbA1c

Evidence topic

HbA1c Reduction

Primary intervention

Tirzepatide

Primary outcomes

  • HbA1c
  • Weight loss dependent effect on HbA1c
  • Weight loss independent effect on HbA1c

Evidence topics

HbA1c ReductionGLP-1 Receptor Agonists

Primary intervention

Tirzepatide

Primary outcomes

HbA1cWeight loss dependent effect on HbA1cWeight loss independent effect on HbA1c

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

3
Evidence pairs
3
Relationships
2
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

2

Related topics

3

Evidence pairs

225

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 3 evidence relationships
  • Includes primary outcome data
  • Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Core evidence

Study findings

The primary outcomes reported in this study.

HbA1c

Tirzepatide → HbA1c

Tirzepatide → HbA1c

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
85
Strong
ConsistencyScore™
100
consistent
Supporting studies: Based on 9 studies
Unlock full evidence details

Weight loss dependent effect on HbA1c

Tirzepatide → Weight loss dependent effect on HbA1c

Tirzepatide → Weight loss dependent effect on HbA1c

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence details

Weight loss independent effect on HbA1c

Tirzepatide → Weight loss independent effect on HbA1c

Tirzepatide → Weight loss independent effect on HbA1c

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

evidence suggest

Evidence Suggest

  • Tirzepatide led to a significant HbA1c reduction of -20 mmol/mol.
  • Weight loss mediated 12%-27% of the HbA1c changes.
  • Differences in HbA1c between tirzepatide and semaglutide were partly independent of weight loss.
who this applies

Who this applies to

  • Adults with type 2 diabetes.
  • Patients seeking weight loss alongside glycemic control.
keep in mind

Keep in Mind

  • The study's findings may not apply to younger populations.
  • Results are based on a specific treatment duration of 40 weeks.
  • Further research is needed to explore long-term effects.
between the lines

Between the Lines

  • Effectiveness data was unclear for some outcomes.
  • The study's population may not be representative of all diabetes patients.
  • Long-term effects beyond 40 weeks were not assessed.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Weight loss dependent effect on HbA1c.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 84.6 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 25 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
25 supporting studiesUpdated: Jul 2026
View Full Evidence

Does Tirzepatide affect weight loss dependent effect on hba1c?

Emerging Evidence

Current evidence does not show a clear benefit of Tirzepatide for Weight loss dependent effect on HbA1c.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Weight loss dependent effect on HbA1c

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence

Does Tirzepatide affect weight loss independent effect on hba1c?

Emerging Evidence

Current evidence does not show a clear benefit of Tirzepatide for Weight loss independent effect on HbA1c.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Weight loss independent effect on HbA1c

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

HbA1c Reduction Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Tirzepatide and HbA1cAll studies on Tirzepatide and Weight loss dependent effect on HbA1cAll studies on Tirzepatide and Weight loss independent effect on HbA1c

Related research

Read related research summaries.

Tirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTirzepatide improves glycemic control and weight loss in type 2 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.